Teppei Morikawa

Summary

Affiliation: University of Tokyo
Country: Japan

Publications

  1. pmc UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy
    Teppei Morikawa
    Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Int J Clin Exp Pathol 6:1367-74. 2013
  2. pmc Tumor TP53 expression status, body mass index and prognosis in colorectal cancer
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, and Department of Medicine Brigham and Women s Hospital, Boston, MA 02215, USA
    Int J Cancer 131:1169-78. 2012
  3. pmc Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 19:1944-53. 2012
  4. ncbi request reprint Phyllodes tumor of the prostate with exuberant glandular hyperplasia
    Teppei Morikawa
    Department of Human Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Pathol Int 56:158-61. 2006
  5. doi request reprint Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer
    Teppei Morikawa
    Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Histopathology 57:885-92. 2010
  6. pmc Recurrent prostatic stromal sarcoma with massive high-grade prostatic intraepithelial neoplasia
    Teppei Morikawa
    Department of Human Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    J Clin Pathol 60:330-2. 2007
  7. doi request reprint Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro
    Teppei Morikawa
    Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Hum Pathol 41:1742-8. 2010
  8. pmc Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer
    Paul Lochhead
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, United States
    Eur J Cancer 48:3405-13. 2012
  9. pmc TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers
    Kaori Shima
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e25062. 2011
  10. pmc Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Havard Medical School, Boston, MA 02215, USA
    Arch Surg 147:715-23. 2012

Detail Information

Publications54

  1. pmc UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy
    Teppei Morikawa
    Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Int J Clin Exp Pathol 6:1367-74. 2013
    ..Taken together, our results suggest that UBE2C is a novel prognostic biomarker as well as a potential therapeutic target in bladder cancer. ..
  2. pmc Tumor TP53 expression status, body mass index and prognosis in colorectal cancer
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, and Department of Medicine Brigham and Women s Hospital, Boston, MA 02215, USA
    Int J Cancer 131:1169-78. 2012
    ..These molecular pathological epidemiology data may support a dual role of TP53 alterations in cell-cycle deregulation and cell autonomy with respect to energy balance status...
  3. pmc Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 19:1944-53. 2012
    ..However, little is known about the prognostic significance of tumor growth pattern, independent of tumoral molecular alterations and other histologic features...
  4. ncbi request reprint Phyllodes tumor of the prostate with exuberant glandular hyperplasia
    Teppei Morikawa
    Department of Human Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Pathol Int 56:158-61. 2006
    ..The final diagnosis was then made as 'phyllodes tumor of the prostate with exuberant glandular hyperplasia'. Atypical stromal cells might provide a clue for the recognition of this rare tumor at initial diagnosis by needle biopsy...
  5. doi request reprint Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer
    Teppei Morikawa
    Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Histopathology 57:885-92. 2010
    ..To examine the immunohistochemical expression and function of ribonucleotide reductase M2 subunit (RRM2), a gemcitabine-related molecule, in bladder cancer...
  6. pmc Recurrent prostatic stromal sarcoma with massive high-grade prostatic intraepithelial neoplasia
    Teppei Morikawa
    Department of Human Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    J Clin Pathol 60:330-2. 2007
    ..Our findings suggest that not only the stromal component but also and the epithelial components of PSS may have malignant potential...
  7. doi request reprint Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro
    Teppei Morikawa
    Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Hum Pathol 41:1742-8. 2010
    ..Our data suggest that ribonucleotide reductase M2 subunit overexpression could be associated with the gastric cancer progression and that suppression of its function is a potential therapeutic strategy in gastric cancer...
  8. pmc Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer
    Paul Lochhead
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, United States
    Eur J Cancer 48:3405-13. 2012
    ..However, the clinical, pathological, molecular and prognostic features of IGF2BP3-positive colorectal cancers remain uncertain...
  9. pmc TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers
    Kaori Shima
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e25062. 2011
    ..However, a role of TGFBR2 or BAX mononucleotide mutation in colorectal cancer as a prognostic biomarker remains uncertain...
  10. pmc Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Havard Medical School, Boston, MA 02215, USA
    Arch Surg 147:715-23. 2012
    ..To identify factors that influence the total and negative lymph node counts in colorectal cancer resection specimens independent of pathologists and surgeons...
  11. pmc Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review
    Xiaoyun Liao
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 18:2257-68. 2012
    ..Thus, we hypothesized that PIK3CA exon 9 and exon 20 mutations might have differential effects on clinical outcome in colorectal cancer, and that concomitant PIK3CA exon 9 and 20 mutations might confer aggressive tumor behavior...
  12. doi request reprint Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma
    Rumi Hino
    Department of Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo ku, Tokyo, Japan
    Cancer Res 69:2766-74. 2009
    ..LMP2A plays an essential role in the epigenetic abnormalities in host stomach cells and in the development and maintenance of EBV-associated cancer...
  13. pmc Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication
    Paul Lochhead
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 105:1151-6. 2013
    ..No evidence existed for a differential prognostic role of BRAF mutation by MSI status (P(interaction) > .50). Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification...
  14. pmc Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer
    Mai Yamauchi
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    Cancer Epidemiol Biomarkers Prev 22:1142-52. 2013
    ....
  15. pmc Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers
    Yu Imamura
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 450 Brookline Ave, Room JF 215C, Boston, MA 02215, USA
    Clin Cancer Res 18:4753-63. 2012
    ..Cox proportional hazards model was used to compute mortality HR, adjusting for potential confounders, including stage, PIK3CA mutations, microsatellite instability, CpG island methylator phenotype, and LINE-1 methylation...
  16. pmc Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 450 Brookline Ave, Rm JF 215C, Boston, MA 02215, USA
    J Natl Cancer Inst 105:130-40. 2013
    ..We tested the hypothesis that CRC family history might confer a higher risk of LINE-1 methylation-low CRC...
  17. pmc Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival
    Xiaoyun Liao
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 367:1596-606. 2012
    ....
  18. pmc Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA
    JAMA 305:1685-94. 2011
    ..Alterations of the WNT signaling pathway and cadherin-associated protein β 1 (CTNNB1 or β-catenin) have been implicated in colorectal carcinogenesis and metabolic diseases...
  19. ncbi request reprint Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma
    Akimasa Hayashi
    Department of Pathology, Graduate School of Medicine, The University of Tokyo, Hongo 7 3 1, Bunkyo ku, Tokyo, 113 0033, Japan
    Virchows Arch 464:463-71. 2014
    ..08; 95 % confidence interval, 1.30-7.32) after nephroureterectomy. Our results suggest that EZH2 may serve as a novel prognostic biomarker and a potential therapeutic target in upper urinary tract carcinoma...
  20. pmc A Prospective Study of Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15) and Risk of Colorectal Cancer
    Raaj S Mehta
    Affiliations of authors Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA RSM, ATC Gastrointestinal Research Group, Institute of Medical Sciences, Aberdeen University, Aberdeen, United Kingdom NB Department of Epidemiology XG, SO, ELG and Department of Nutrition MS, KW, XG, ELG, Harvard School of Public Health, Boston, MA Department of Pathology, University of Tokyo, Tokyo, Japan TM Channing Division of Network Medicine, Department of Medicine CSF, ELG, ATC and Department of Pathology SO, Brigham and Women s Hospital and Harvard Medical School, Boston, MA Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA CSF, SO
    J Natl Cancer Inst 106:dju016. 2014
    ..Chronic inflammation plays a role in the development of colorectal cancer (CRC). The novel plasma inflammatory biomarker macrophage inhibitory cytokine-1 (MIC-1, GDF15) may have a direct mechanistic role in colorectal carcinogenesis...
  21. pmc STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:1452-62. 2011
    ..Although the STAT3 signaling pathway is a potential drug target, clinical, pathologic, molecular, or prognostic features of STAT3-activated colorectal cancer remain uncertain...
  22. pmc Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study
    Aya Kuchiba
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 104:415-20. 2012
    ..9 and 7.1, respectively, per 100,000 person-years. This molecular pathological epidemiology study supports a role of energy metabolism in colorectal cancer pathogenesis...
  23. pmc A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification
    Reiko Nishihara
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Epidemiology, Harvard School of Public Health, 450 Brookline Avenue, Room JF 215C, Boston, MA 02215, USA
    Am J Epidemiol 178:84-100. 2013
    ..These molecular pathological epidemiology data suggest a protective effect of smoking cessation on a DNA methylation-related carcinogenesis pathway leading to CIMP-high colorectal cancer. ..
  24. pmc Aspirin use and risk of colorectal cancer according to BRAF mutation status
    Reiko Nishihara
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    JAMA 309:2563-71. 2013
    ....
  25. pmc Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum
    Mai Yamauchi
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Gut 61:847-54. 2012
    ..Considering a possible role of bowel contents (including microbiome) in carcinogenesis, this study hypothesised that tumour molecular features might gradually change along bowel subsites, rather than change abruptly at splenic flexure...
  26. pmc Long-term colorectal-cancer incidence and mortality after lower endoscopy
    Reiko Nishihara
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    N Engl J Med 369:1095-105. 2013
    ..Colonoscopy and sigmoidoscopy provide protection against colorectal cancer, but the magnitude and duration of protection, particularly against cancer of the proximal colon, remain uncertain...
  27. pmc Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA
    Cancer Res 73:1600-10. 2013
    ..Furthermore, they suggest that energy balance and metabolism status exerts its effect in a specific carcinogenesis pathway that is less likely dependent on WNT/CTNNB1 activation. Cancer Res; 73(5); 1600-10. ©2012 AACR...
  28. pmc Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations
    Hongmei Nan
    Affiliations of authors Division of Cancer Epidemiology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD HN Channing Division of Network Medicine, Department of Medicine HN, DJH, ELG, CSF, ATC and Department of Epidemiology DJH, PK, ELG, SO, Brigham and Women s Hospital and Harvard Medical School, Boston, MA Center for Molecular Oncologic Pathology TM, YI, AK, MY, SO, Department of Medical Oncology TM, MS, YI, AK, MY, CSF, SO, MLF, and Department of Biostatistics and Computational Biology LW, Dana Farber Cancer Institute, Boston, MA Department of Epidemiology DJH, ELG, SO and Department of Nutrition, Harvard School of Public Health, Boston, Simancas 47130
    J Natl Cancer Inst 105:1852-61. 2013
    ....
  29. pmc No evidence for interference of h&e staining in DNA testing: usefulness of DNA extraction from H&E-stained archival tissue sections
    Teppei Morikawa
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Room JF 208E, Boston, MA 02215, USA
    Am J Clin Pathol 138:122-9. 2012
    ..Our data provide no evidence for an interfering effect of H&E staining on DNA testing, suggesting that DNA from H&E-stained sections can be effectively used for routine DNA testing...
  30. pmc Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival
    Xabier Garcia-Albeniz
    Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
    Carcinogenesis 34:292-8. 2013
    ..These findings suggest that individuals with this SMAD7 variant that develop CRC are more probably to have tumors with greater invasiveness and methylation of RUNX3, which potentially contributes to their poorer observed survival...
  31. pmc MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers
    Kaori Shima
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer Causes Control 22:301-9. 2011
    ..MGMT promoter hypermethylation and epigenetic silencing often occur as early events in carcinogenesis. However, prognostic significance of MGMT alterations in colorectal cancer remains uncertain...
  32. doi request reprint Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma
    Masayoshi Nagata
    Division of Molecular Pathology, Institute of Medical Science, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Int J Cancer 130:1329-37. 2012
    ..Finally, introduction of CADM4 into an RCC cell line, 786-O, dramatically suppressed tumor formation in nude mice. These findings suggest that CADM4 is a novel tumor suppressor candidate in RCCC acting with its binding partner 4.1B...
  33. doi request reprint Subepithelial myofibroblast in lung adenocarcinoma: a histological indicator of excellent prognosis
    Daisuke Matsubara
    Department of Pathology, Jichi Medical University, Shimotsuke, Japan
    Mod Pathol 22:776-85. 2009
    ..A subset of invasive adenocarcinomas retains subepithelial myofibroblasts. Analysis of subepithelial myofibroblasts may be helpful in identifying a subset of lung adenocarcinoma with excellent prognosis...
  34. ncbi request reprint c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis
    Yu Nakamura
    Department of Human Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Cancer Sci 98:1006-13. 2007
    ..c-Met activation may play special roles in the papillary subtype and in well differentiated lung adenocarcinomas...
  35. ncbi request reprint Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome
    Yusuke Sato
    Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Science 344:917-20. 2014
    ..These results highlight the major role of cAMP-independent activation of cAMP/PKA signaling by somatic mutations in corticotropin-independent Cushing's syndrome, providing insights into the diagnosis and therapeutics of this syndrome. ..
  36. ncbi request reprint Prognostic significance of CD204-positive macrophages in upper urinary tract cancer
    Takashi Ichimura
    Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Ann Surg Oncol 21:2105-12. 2014
    ....
  37. pmc Restriction of intestinal stem cell expansion and the regenerative response by YAP
    Evan R Barry
    Stem Cell Program and Department of Hematology Oncology, Children s Hospital, Boston, Massachusetts 02115, USA
    Nature 493:106-10. 2013
    ..Additionally, our findings have important implications for the targeting of YAP in human malignancies...
  38. pmc Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression
    Jennifer H Lin
    Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer Res 72:3020-8. 2012
    ..Together, our molecular pathological epidemiology findings suggest a preventive effect of hormone therapy against colorectal carcinogenesis that depends, in part, on loss of cyclin-dependent kinase inhibitor CDKN1A...
  39. ncbi request reprint Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition
    Reem Ibrahim
    Molecular Pathology Laboratory, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    Hum Pathol 45:1397-405. 2014
    ..0089). We herein highlighted the importance of PRMT5 expression, especially its cytoplasmic expression, in the process of epithelial-mesenchymal transition and loss of the bronchial epithelial phenotype of lung adenocarcinoma. ..
  40. pmc Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer
    Yuzuri Tsurumaki Sato
    Department of Urology, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    BMC Urol 14:13. 2014
    ..We evaluated the long-term results of radical prostatectomy and immediate adjuvant androgen deprivation therapy in Japanese patients with pT3N0M0 prostate cancer...
  41. pmc Metastatic seminomas in lymph nodes: CD10 immunoreactivity can be a pitfall of differential diagnosis
    Yasunori Ota
    Department of Pathology, Toranomon Hospital Tokyo, Japan
    Int J Clin Exp Pathol 6:498-502. 2013
    ..We further evaluated CD10 expression in a series of seminomas (n=16). Strong positivity was observed in 14 cases; partial and weak positivity, in 2 cases. These findings should be considered in the differential diagnosis of seminoma...
  42. pmc Prognostic significance of MTOR pathway component expression in neuroendocrine tumors
    Zhi Rong Qian
    Zhi Rong Qian, Monica Ter Minassian, Jennifer A Chan, Yu Imamura, Susanne M Hooshmand, Aya Kuchiba, Teppei Morikawa, Lauren K Brais, Anastassia Daskalova, Rachel Heafield, Charles S Fuchs, Shuji Ogino, Matthew H Kulke, Dana Farber Cancer Institute and Harvard Medical School Monica Ter Minassian, Xihong Lin, David C Christiani, Shuji Ogino, Harvard School of Public Health David C Christiani, Massachusetts General Hospital, Harvard Medical School Charles S Fuchs, Shuji Ogino, Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 31:3418-25. 2013
    ..We explored whether expression of MTOR pathway components has prognostic significance in NET patients...
  43. pmc HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients
    Yuka Sasaki
    Department of Molecular Pathology, Graduate School of Medicine, Yokohama City University Yokohama, Japan
    Int J Clin Exp Pathol 7:699-708. 2014
    ..0284) and multivariate analysis (p=0.0034). The results suggest that HER2 positivity in UUTUC is an independent predictive marker for early recurrence of urothelial carcinoma in the residual urinary bladder after surgery. ..
  44. doi request reprint Identification of chromosomal aberrations of metastatic potential in colorectal carcinoma
    Shogo Yamamoto
    Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, 4 6 1 Komaba, Tokyo, Japan
    Genes Chromosomes Cancer 49:487-96. 2010
    ..Consequently, CRC with and without liver metastasis harbor similar chromosomal aberrations, and chromosomal aberration at 6q, 20p, and 20q may be involved in the process of liver metastasis of CRC...
  45. ncbi request reprint Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway
    Tao Wang
    Department of Human Pathology, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, 113 0033, Tokyo, Japan
    Cancer Sci 98:506-11. 2007
    ..Thus, the present study demonstrates the importance of the EGFR pathway in the increased motility of cancer cells that occurs in a hypoxic tumor environment...
  46. ncbi request reprint IgG4-related periureteral fibrosis presenting as a unilateral ureteral mass
    Hiroyuki Abe
    Department of Pathology, Asahi General Hospital, Chiba, Japan
    Pathol Res Pract 207:712-4. 2011
    ..It is important to consider IgG4-related sclerosing disease in the differential diagnosis of a unilateral ureteral mass...
  47. pmc Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behavior
    Akimasa Hayashi
    Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Genome Science Division, Research Center for Advanced Science and Technology RCAST, The University of Tokyo, Tokyo, Japan
    PLoS ONE 9:e91330. 2014
    ..These findings demonstrate that image analyzer-assisted H-scores of H3K27ac and H3K27me3 identified an aggressive subgroup of HCC, and could serve as a prognostic marker for HCC. ..
  48. doi request reprint Integrated molecular analysis of clear-cell renal cell carcinoma
    Yusuke Sato
    Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Nat Genet 45:860-7. 2013
    ..This integrated molecular analysis unmasked new correlations between DNA methylation, gene mutation and/or gene expression and copy number profiles, enabling the stratification of clinical risks for patients with ccRCC. ..
  49. ncbi request reprint Oncofetal protein glypican-3 in testicular germ-cell tumor
    Satoshi Ota
    Department of Pathology, Graduate School of Medicine, University of Tokyo, Hongo 7 3 1, Bunkyo, Tokyo, 113 0033, Japan
    Virchows Arch 449:308-14. 2006
    ..Thus, GPC3 is a unique oncofetal protein, which is useful as an immunohistochemical marker for GCT differentiated to extraembryonic tissue, especially YST...
  50. pmc Epstein-Barr virus-associated gastric carcinoma: a distinct carcinoma of gastric phenotype by claudin expression profiling
    Aya Shinozaki
    Department of Pathology, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 0033, Japan
    J Histochem Cytochem 57:775-85. 2009
    ..EBV-associated GC may undergo distinct carcinogenic processes, which differ from those of EBV-negative GC...
  51. doi request reprint Langerhans cell histiocytosis of the urinary bladder in a patient with bladder cancer previously treated with intravesical Bacillus Calmette-Guérin therapy
    Satoe Numakura
    Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Pathol Res Pract 210:123-6. 2014
    ..To avoid misdiagnosis, urologists and pathologists should be aware that LCH may develop in the urinary bladder after intravesical BCG therapy for bladder cancer. ..
  52. pmc Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling
    David Horst
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer Res 72:1547-56. 2012
    ..Furthermore, they suggest that MAPK signaling is a critical modifier of intratumoral heterogeneity that contributes significantly to determining the impact of WNT activity on stemness phenotypes in colon cancer cells...
  53. ncbi request reprint Erdheim-Chester disease with an 18F-fluorodeoxyglucose-avid breast mass and BRAF V600E mutation
    Toshihiro Furuta
    Department of Radiology, Research Hospital, The Institute of Medical Science, The University of Tokyo, 4 6 1, Shirokanedai, Minato ku, Tokyo, 108 8639, Japan
    Jpn J Radiol 32:282-7. 2014
    ..Both specimens revealed involvement by histiocytic infiltrates with features suggestive of ECD. The BRAF V600E mutation was detected by DNA sequencing and immunohistochemistry. ..